Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Revlimid

10mgs PO daily for 21 days of each 28 day cycle. Number of cycles: total of 24 or until subject relapses or unacceptable toxicity develops.

Trial Locations (1)

M5G 2M9

University Health Network, Princess Margaret Hospital, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

University Health Network, Toronto

OTHER